Skip to main content

Market Overview

Luminex Secures BARDA Funding To Develop And Validate Flu/COVID-19 Combo Respiratory Panel

  • Luminex Corporation (NASDAQ: LMNX) has received $11.3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA). It will support the rapid development and validation of a respiratory panel combining Flu A/B & respiratory syncytial virus targets with the SARS-CoV-2 target that can run on all ARIES Systems.
  • These six and 12-cassette systems are automated molecular diagnostic platforms and produce results in less than two hours.
  • Luminex developed the original ARIES SARS-CoV-2 Assay with financial support from BARDA and received an Emergency Use Authorization from FDA for COVID-19 testing in April last year.
  • Luminex will submit the targeted multiplex respiratory panel, the ARIES Flu A/B & RSV+SARS-CoV-2 Assay, to the FDA for Emergency Use Authorization as soon as possible.
  • Price Action: LMNX stock closed 0.34% lower at $29.56 on Thursday.

Related Articles (LMNX)

View Comments and Join the Discussion!

Posted-In: Covid-19News Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at